Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
E-pub ahead of print

Proinflammatory biomarkers are associated with prediabetes in patients with schizophrenia

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Expert Consensus on Screening and Assessment of Cognition in Psychiatry

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Neuronal underpinnings of cognitive impairment and - improvement in mood disorders

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Anhedonia and cognitive function in adults with MDD: results from the International Mood Disorders Collaborative Project

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND: Treatment with antipsychotics is associated with an increased risk of type 2 diabetes mellitus (T2D), and increased levels of inflammatory biomarkers are present in patients with T2D. We previously demonstrated that the glucagon-like peptide-1 receptor agonist liraglutide significantly reduced glucometabolic disturbances and body weight in prediabetic, overweight/obese schizophrenia-spectrum disorder patients treated with clozapine or olanzapine. This study aims to assess the involvement of cytokines in the therapeutic effects of liraglutide.

METHODS: Serum concentrations of 10 cytokines (interferon-γ [IFN-γ], tumor necrosis factor-α, interleukin 1β [IL-1β], IL-2, IL-4, IL-6, IL-8, IL-10, IL-12p70, and IL-13) from fasting prediabetic and normal glucose-tolerant (NGT) patients with schizophrenia-spectrum disorders were measured using multiplexed immunoassays. Prediabetic patients were randomized to 16 weeks of treatment with liraglutide or placebo, and cytokines were measured again at the end of the treatment.

RESULTS: IFN-γ (1.98 vs 1.17 pg/ml, P = .001), IL-4 (0.02 vs 0.01 pg/ml, P < .001), and IL-6 (0.73 vs 0.46 pg/ml, P < .001) were significantly higher in prediabetic (n = 77) vs NGT patients (n = 31). No significant changes in cytokine levels following treatment with liraglutide (n = 37) vs placebo (n = 40) were found.

CONCLUSION: Prediabetic vs NGT patients with schizophrenia treated with clozapine or olanzapine had increased serum levels of several proinflammatory cytokines, further substantiating the link between inflammation and T2D. Treatment with liraglutide did not affect the investigated cytokines. Further testing of these findings in larger numbers of individuals is needed.

Original languageEnglish
JournalCNS Spectrums
Pages (from-to)1-8
Number of pages8
Publication statusE-pub ahead of print - 14 Dec 2020

    Research areas

  • 50 schizophrenia, Clozapine, Glp-1, Inflammation, Liraglutide, Olanzapine, Prediabetes

ID: 61525025